Ongoing Clinical Research

OIC is at the forefront of clinical trials and cutting edge technology. Here, you can research study opportunities for HIV vaccines, HIV medications, and Hepatitis C medications.

If you are eligible, you will receive study drugs, labs, and medical treatments related to the study at no cost.

HIV STUDIES

  • GSK200911 (CURRENTLY ENROLLING)
    • A phase 2a, Multicenter, randomized, adaptive, open-label, dose ranging study to evaluate the antiviral effect, safety, tolerability and pharmacokinetics of Cobicstat-boosted GSK2838232 monotherapy over 10 days in HIV-1 infected treatment-Naïve adults.
  • ABI-1968-201 (CURRENTLY ENROLLING)
    • Open-Label study to evaulate the safety tolderability and pharmacokinetics of single and multiple doses of topical ABI-1968 in subjects with anal high-grade squamous intraepithelial lesions
  • MK8591-011 (CURRENTLY ENROLLING)
    • A phase 2B, randomized, double-blind, active comparator controlled dose ranging clincial trial to evaluate the safety, tolerability, antiretroviral activity and pharmacokinectics  of MK-8591 given in combination with Doravirine and Lamuvidine in HIV-1 infected treatment naive adults
  • REPRIEVE (CURRENTLY ENROLLING)
    • People infected with HIV are at risk for cardiovascular disease.  This study will evaluate the use of pitavastatin to reduce the risk of CVD in adults infected with HIV who are on antiretroviral therapy.
  • PRO140_CD03 (CURRENTLY ENROLLING)
    • A phase 2b/3 multicenter study to assess the treatment strategy of using PRO140 SC as long acting single agent maintenance therapy for 48 weeks in virologically suppressed subjects with CCR5 topic HIV-1 Infection.
  • GS-US-382-3961 (CURRENTLY ENROLLING)
    • A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers
  • 204862 (CURRENTLY ENROLLING) 
    • Link Pending – A phase III, ramdomized, multicenter, parallel-group, non-inferioriy study evaluating the efficacy, safety and tolerability of switching to dolutegravir plus lamividine in HIV-1 infected adults who are virologically suppressed
  • GS-US-382-1450 (CURRENTLY ENROLLING)
    • A phase 1B, Randomized, Blinded, Placebo- Controlled dose esculation study of the safety and biological activity of GS-9620 in HIV-1 Infected, Virologically supressed adults.
  • ABI-1968-201 (CURRENTLY ENROLLING)
    • Open-Label study to evaulate the safety tolderability and pharmacokinetics of single and multiple doses of topical ABI-1968 in subjects with anal high-grade squamous intraepithelial lesions
  • IAVI T001 (CURRENTLY ENROLLING)
    • A phase 1 placebo controlled clinical trial of the safety, pharmacokinetics and antiviral activity of PGT121 monoclonal antibody in HIV-unifected and HIV-infected adults
  • PRO140-CD02 (CURRENTLY ENROLLING)
    • A multicenter, randomized, double-blind, placebo controlled trial, followed by a single-arm treatment of PRO140 in combination with optimized background therapy in treatment-experienced HIV-1 subjects.
  • ABI-1968-201 (CURRENTLY ENROLLING)
    • Open-Label study to evaulate the safety tolderability and pharmacokinetics of single and multiple doses of topical ABI-1968 in subjects with anal high-grade squamous intraepithelial lesions
  • IAVI T001 (CURRENTLY ENROLLING)
    • A phase 1 placebo controlled clinical trial of the safety, pharmacokinetics and antiviral activity of PGT121 monoclonal antibody in HIV-unifected and HIV-infected adults

HCV STUDIES

  • 56136379HPB2001  (CURRENTLY ENROLLING)
    • A phase2b, Randomized, partially-blind, placebo controlled study to access the efficacy, safety, amd the phamacokinetics of 24 weeks of treatment with multiple doses of JNJ-56136379 as monotherapy and in combination with a Nucleos(t)ide analog in subjects with chronic Hepatitis B virus infection.
  • 3152-301-002 (CURRENTLY ENROLLING)
    •  A phase 3, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of Cenicriviroc for the treatment of Liver Fibrosis in adult subjects with Nonalcoholic Steatohepatitis.
  • PB-WOTFORHEPC (CURRENTLY ENROLLING)
    • Evaluation of wirelessy observed therapy to optimize adherence in patients with Hepatitis C and increased risk for nonadhearence to treatment.
  • 56136379HPB2001  (CURRENTLY ENROLLING)
    • A phase2b, Randomized, partially-blind, placebo controlled study to access the efficacy, safety, amd the phamacokinetics of 24 weeks of treatment with multiple doses of JNJ-56136379 as monotherapy and in combination with a Nucleos(t)ide analog in subjects with chronic Hepatitis B virus infection.
  • 3152-301-002 (CURRENTLY ENROLLING)
    • A phase 3, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of Cenicriviroc for the treatment of Liver Fibrosis in adult subjects with Nonalcoholic Steatohepatitis.
  • PB-WOTFORHEPC (CURRENTLY ENROLLING)
    • Evaluation of wirelessy observed therapy to optimize adherence in patients with Hepatitis C and increased risk for nonadhearence to treatment.
  • B16-439 (CURRENTLY ENROLLING)
    • A phase 3b, Multicenter, Randomized, Open-Label, Pragmatic study of Glecaprevir / Pibrentasvir (G/P) +/- Ribavirin for GT1 subjects with Chronic Hepatitis C previously treated with Ns5A Inhibitor + Sofosbuvir Therapy.

OTHER STUDIES

  • REPRIEVE (CURRENTLY ENROLLING)
    • People infected with HIV are at risk for cardiovascular disease.  This study will evaluate the use of pitavastatin to reduce the risk of CVD in adults infected with HIV who are on antiretroviral therapy.

 

  • ABI-1968-201 (CURRENTLY ENROLLING)
    • Open-Label study to evaulate the safety tolderability and pharmacokinetics of single and multiple doses of topical ABI-1968 in subjects with anal high-grade squamous intraepithelial lesions
  • IAVI T001 (CURRENTLY ENROLLING)
    • A phase 1 placebo controlled clinical trial of the safety, pharmacokinetics and antiviral activity of PGT121 monoclonal antibody in HIV-unifected and HIV-infected adults
  • 56136379HPB2001 (CURRENTLY ENROLLING)
    • A phase2b, Randomized, partially-blind, placebo controlled study to access the efficacy, safety, amd the phamacokinetics of 24 weeks of treatment with multiple doses of JNJ-56136379 as monotherapy and in combination with a Nucleos(t)ide analog in subjects with chronic Hepatitis B virus infection.

 

Source: ClinicalTrials.gov

Clinical Trial Inquiry

To schedule an appointment with one of our board certified specialists call
(407) 647-3960 or click here to request an appointment.